Atrium Therapeutics, Inc. - Common Stock (RNA)

CUSIP: 05370A108

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class
Equity / Common Stock
Shares outstanding
150,858,761
Total 13F shares
140,543,535
Share change
-20,728,172
Total reported value
$10,136,861,240
Put/Call ratio
408%
Price per share
$72.13
Number of holders
335
Value change
-$695,624,687
Number of buys
209
Number of sells
165

Quarterly Holders Quick Answers

What is CUSIP 05370A108?
CUSIP 05370A108 identifies RNA - Atrium Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Atrium Therapeutics, Inc. - Common Stock (RNA) as of Q4 2025

As of 31 Dec 2025, Atrium Therapeutics, Inc. - Common Stock (RNA) was held by 335 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 140,543,535 shares. The largest 10 holders included VANGUARD GROUP INC, BlackRock, Inc., RA CAPITAL MANAGEMENT, L.P., JANUS HENDERSON GROUP PLC, Balyasny Asset Management L.P., Pentwater Capital Management LP, Avoro Capital Advisors LLC, HBK INVESTMENTS L P, STATE STREET CORP, and GOLDMAN SACHS GROUP INC. This page lists 335 institutional shareholders reporting positions in this security for the Q4 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.